Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP9 | P14780 | 2/20 | 0.53 |
| ▸ | MMP13 | P45452 | 2/20 | 0.53 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27885973 | 0.86 | RAB9A (0.40) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL2142883 | 0.85 | MMP1 (0.50) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL13547516 | 0.84 | MAPT (0.53) | MMP1MMP2MMP9MMP13ALDH1A1 | |
| SCHEMBL9385647 | 0.82 | HTR2B (0.44) | MMP1MMP2MMP9MMP13L3MBTL1 | |
| SCHEMBL1246008 | 0.82 | PLA2G4A (0.55) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL2839000 | 0.82 | MMP1 (0.54) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL457576 | 0.82 | MMP2 (0.54) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL3698353 | 0.80 | PLA2G4A (0.57) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL13614850 | 0.80 | MMP1 (0.53) | MMP1MMP2MMP9MMP13PLA2G4A | |
| SCHEMBL2497828 | 0.80 | MMP1 (0.53) | MMP1MMP2MMP9MMP13PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 71 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | claimed |
| CN-106281113-A | A kind of high temperature resistant seccotine | 无锡万能胶粘剂有限公司 | 2017-01-04 | — | — | CN | claimed |
| CN-122070275-A | Heterocyclic compound and application thereof | 成都麻沸散医药科技有限公司 | 2026-05-19 | — | — | CN | disclosed |
| WO-2025003987-A1 | NOVEL CARBOXAMIDE DERIVATIVE COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 동화약품주식회사 | 2025-01-02 | — | — | WO | disclosed |
| CN-115776887-A | MDM2 degrading agents and uses thereof | 凯麦拉医疗公司 | 2023-03-10 | — | — | CN | disclosed |
| CN-114450284-A | 6, 7-dihydro-5H-pyrido [2,3-C ] pyridazine derivatives and related compounds as BCL-XL protein inhibitors and pro-apoptotic agents for the treatment of cancer | 法国施维雅药厂 | 2022-05-06 | — | — | CN | disclosed |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | BIOGEN MA INC. | 2022-03-24 | — | — | US | disclosed |
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AMGEN INC. (US) | 2021-06-29 | — | — | US | disclosed |
| EP-3541805-B1 | HETEROARYL-SUBSTITUTED TRIAZOLES AS APJ RECEPTOR AGONISTS | AMGEN INC (US) | 2020-10-14 | — | — | EP | disclosed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | disclosed |
| CN-110156874-A | Cyclodepsipeptide compound | 恩库勒公司 | 2019-08-23 | — | — | CN | disclosed |
| US-20100041638-A1 | Chemical Compounds 293 | ASTRAZENECA AB (SE) | 2010-02-18 | — | — | US | disclosed |
| WO-2009144494-A1 | PHENOXYPYRIDINYLAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PDE4 MEDIATED DISEASE STATES | ASTRAZENECA AB (SE) | 2009-12-03 | — | — | WO | disclosed |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | METHLYGENE INC. (CA) | 2008-10-16 | — | — | US | disclosed |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | SHIONOGI & CO. LTD. (JP) | 2008-05-01 | — | — | US | disclosed |
| WO-2008006790-A1 | INDOLE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2008-01-17 | — | — | WO | disclosed |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | METHYLGENE, INC. (CA) | 2008-01-03 | — | — | US | disclosed |
| WO-2007103550-A2 | SUBSTITUTED AMINOTHIAZOLE DERIVATIVES WITH ANTI-HCV ACTIVITY | ACHILLION PHARMACEUTICALS, INC. (US) | 2007-09-13 | — | — | WO | disclosed |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | METHYLGENE, INC. | 2007-01-04 | — | — | US | disclosed |
| EP-0195817-B1 | CARBOXYALKYLDIPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SCHERING CORPORATION (US) | 1989-10-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11046680-B1 | Heteroaryl-substituted triazoles as APJ receptor agonists | AGTR1, AGTR2, TBXA2R | MMP1 4623/4885MMP2 4175/4885MMP9 2888/4885 |
| US-20100041638-A1 | Chemical Compounds 293 | PDE4B, PDE4A, PDE3B | MMP1 188/4885MMP2 85/4885MMP9 127/4885 |
| US-20070004675-A1 | Inhibitors of VEGF receptor and HGF receptor signaling | HGF, MET, FLT1 | MMP1 1074/4885MMP2 538/4885MMP9 416/4885 |
| US-20080103139-A1 | 3-Carbamoyl-2-Pyridone Derivative | CNR1, CNR2, HRH4 | MMP1 3721/4885MMP2 3948/4885MMP9 4487/4885 |
| US-20080255155-A1 | KINASE INHIBITORS AND USES THEREOF | ABL1, MAP3K20, MAP3K1 | MMP1 2617/4885MMP2 2075/4885MMP9 1774/4885 |
| US-20080004273-A1 | Inhibitors of protein tyrosine kinase activity | HGF, ERBB2, MET | MMP1 1456/4885MMP2 896/4885MMP9 1022/4885 |
| US-20220089592-A1 | IMIDAZO[1,2-A]PYRIDINYL DERIVATIVES AS IRAK4 INHIBITORS | IRAK4, IRAK2, IRAK1 | MMP1 3354/4885MMP2 3958/4885MMP9 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.